Gene Therapy for Chinese Hemophilia A

NARecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Hemophilia AGene Therapy
Interventions
GENETIC

Injection of GS001

"Patients will be enrolled sequentially every 3 weeks or more between cohorts. Dose escalation may occur after a single patient has been safely dosed if the resulting FVIII activity at Week 3 is \< 5 IU/dL.The dose levels are as follows:~1. 2×10\^12 vg/kg~2. 6×10\^12vg/kg or other recommended doses~3. 2×10\^13 vg/kg or other recommended doses"

Trial Locations (1)

300020

RECRUITING

Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER